Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Operating income3 4 5 6 -$285.4M in 2024+1972% since 2018 -$300.0M -$200.0M -$100.0M 0 2018: -$13.8M -$13.8M 2018 2019: -$45.7M -$45.7M 2019 +231% 2020: -$80.2M -$80.2M 2020 +76% 2021: -$100.9M -$100.9M 2021 +26% 2022: -$115.2M -$115.2M 2022 +14% 2023: -$172.9M -$172.9M 2023 +50% 2024: -$285.4M -$285.4M 2024 +65% Net income7 4 8 5 6 9 -$252.1M in 2024+208% since 2018 -$300.0M -$200.0M -$100.0M 0 2018: -$81.7M -$81.7M 2018 2019: -$43.8M -$43.8M 2019 −46% 2020: -$79.2M -$79.2M 2020 +81% 2021: -$100.8M -$100.8M 2021 +27% 2022: -$112.0M -$112.0M 2022 +11% 2023: -$151.8M -$151.8M 2023 +35% 2024: -$252.1M -$252.1M 2024 +66% Operating income10 9 -$90.2M in Q3 FY2025+12% since Q2 FY2025 -$100.0M -$75.0M -$50.0M -$25.0M 0 Q2 FY2025: -$80.9M -$80.9M Q2 FY2025 Q3 FY2025: -$90.2M -$90.2M Q3 FY2025 +12% Net income10 9 -$81.6M in Q3 FY2025+15% since Q2 FY2025 -$100.0M -$75.0M -$50.0M -$25.0M 0 Q2 FY2025: -$70.7M -$70.7M Q2 FY2025 Q3 FY2025: -$70.7M -$70.7M Q3 FY2025 +0% Q2 FY2025: -$70.5M -$70.5M Q2 FY2025 −0% Q3 FY2025: -$70.5M -$70.5M Q3 FY2025 +0% Q3 FY2025: -$81.6M -$81.6M Q3 FY2025 +16% Fiscal year 2018 2019 2020 2021 2022 2023 2024 2025 Research and development $11.9M3 $37.0M4 $64.9M4 $81.8M5 $85.3M6 $141.8M6 $247.5M6 Operating income -$13.8M3 -$45.7M4 -$80.2M4 -$100.9M5 -$115.2M6 -$172.9M6 -$285.4M6 Interest $739.0K6 $3.1M6 $4.7M6 Income tax $24.0K4 Net income -$81.7M7 -$43.8M4 -$79.2M8 -$100.8M5 -$112.0M6 -$151.8M9 -$252.1M9 Earnings per share -$2.895 -$2.876 -$2.896 -$3.756 Earnings per share (diluted) -$2.904 -$2.524 -$2.895 -$2.876 -$2.896 -$3.756
Total assets3 11 4 12 5 6 $825.9M in 2024+970% since 2018 0 $250.0M $500.0M $750.0M $1.0B 2018: $77.2M $77.2M 2018 2019: $138.1M $138.1M 2019 +79% 2020: $273.3M $273.3M 2020 +98% 2021: $195.5M $195.5M 2021 −28% 2022: $356.6M $356.6M 2022 +82% 2023: $580.3M $580.3M 2023 +63% 2024: $825.9M $825.9M 2024 +42% Total liabilities3 11 4 12 5 6 $75.8M in 2024+3135% since 2018 0 $20.0M $40.0M $60.0M $80.0M 2018: $2.3M $2.3M 2018 2019: $9.4M $9.4M 2019 +301% 2020: $14.6M $14.6M 2020 +56% 2021: $26.4M $26.4M 2021 +81% 2022: $30.0M $30.0M 2022 +13% 2023: $45.0M $45.0M 2023 +50% 2024: $75.8M $75.8M 2024 +69% Shareholders’ equity4 5 6 $750.1M in 2024-$250.0M 0 $250.0M $500.0M $750.0M $1.0B 2018: -$49.9M -$49.9M 2018 2019: $128.7M $128.7M 2019 2020: $258.7M $258.7M 2020 +101% 2021: $169.1M $169.1M 2021 −35% 2022: $326.6M $326.6M 2022 +93% 2023: $535.3M $535.3M 2023 +64% 2024: $750.1M $750.1M 2024 +40% Cash3 11 4 12 5 6 $340.2M in 2024+348% since 2018 0 $100.0M $200.0M $300.0M $400.0M 2018: $76.0M $76.0M 2018 2019: $64.8M $64.8M 2019 −15% 2020: $187.2M $187.2M 2020 +189% 2021: $150.5M $150.5M 2021 −20% 2022: $249.8M $249.8M 2022 +66% 2023: $234.2M $234.2M 2023 −6% 2024: $340.2M $340.2M 2024 +45% Total assets10 9 $1.0B in Q3 FY2025−9% since Q2 FY2025 0 $500.0M $1.0B $1.5B Q2 FY2025: $1.1B $1.1B Q2 FY2025 Q3 FY2025: $1.0B $1.0B Q3 FY2025 −9% Total liabilities10 9 $47.9M in Q3 FY2025−42% since Q2 FY2025 0 $25.0M $50.0M $75.0M $100.0M Q2 FY2025: $83.3M $83.3M Q2 FY2025 Q3 FY2025: $47.9M $47.9M Q3 FY2025 −42% Shareholders’ equity10 9 $957.6M in Q3 FY2025−12% since Q2 FY2025 0 $500.0M $1.0B $1.5B Q2 FY2025: $1.1B $1.1B Q2 FY2025 Q3 FY2025: $1.1B $1.1B Q3 FY2025 +0% Q2 FY2025: $1.0B $1.0B Q2 FY2025 −5% Q3 FY2025: $1.0B $1.0B Q3 FY2025 +0% Q3 FY2025: $957.6M $957.6M Q3 FY2025 −7% Cash10 9 $176.0M in Q3 FY2025−20% since Q2 FY2025 0 $100.0M $200.0M $300.0M Q2 FY2025: $220.4M $220.4M Q2 FY2025 Q3 FY2025: $176.0M $176.0M Q3 FY2025 −20% Fiscal year 2018 2019 2020 2021 2022 2023 2024 2025 Cash $76.0M3 $64.8M11 $187.2M4 $150.5M12 $249.8M5 $234.2M6 $340.2M6 Current assets $77.1M3 $138.0M11 $271.3M4 $193.6M12 $355.2M5 $560.0M6 $770.4M6 Total assets $77.2M3 $138.1M11 $273.3M4 $195.5M12 $356.6M5 $580.3M6 $825.9M6 Current liabilities $2.3M3 $9.4M11 $13.1M4 $25.1M12 $19.1M5 $19.1M6 $39.8M6 Total liabilities $2.3M3 $9.4M11 $14.6M4 $26.4M12 $30.0M5 $45.0M6 $75.8M6 Shareholders’ equity -$49.9M4 $128.7M4 $258.7M5 $169.1M6 $326.6M6 $535.3M6 $750.1M6 Shares outstanding 239.0K shares3 28.6M shares11 34.7M shares4 34.9M shares12 46.9M shares5 55.8M shares6 72.4M shares6 79.6M shares6
Cash from operations3 4 5 6 -$230.1M in 2024+4875% since 2018 -$300.0M -$200.0M -$100.0M 0 2018: -$4.6M -$4.6M 2018 2019: -$35.6M -$35.6M 2019 +670% 2020: -$70.8M -$70.8M 2020 +99% 2021: -$79.7M -$79.7M 2021 +13% 2022: -$92.5M -$92.5M 2022 +16% 2023: -$145.4M -$145.4M 2023 +57% 2024: -$230.1M -$230.1M 2024 +58% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2018 2019 2020 2021 2022 2023 2024 2025 Cash from operations -$4.6M3 -$35.6M4 -$70.8M4 -$79.7M5 -$92.5M6 -$145.4M6 -$230.1M6 Capital spending $148.0K4 Free cash flow -$71.0M Dividend per share $0.003 $0.0011 $0.004 $0.0012 $0.005 $0.006
Compare Akero Therapeutics, Inc. with another company
Recent filings
Dec 9, 2025 8-K Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Dec 9, 2025 4 Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
